Search results | teva


Partnering Agreements with Teva

This report provides all the information you require to better understand Teva and its partnering interests and activities over the past seven years.


Teva Pharmaceuticals

Teva Pharmaceuticals is a top pharmaceutical company based in Petach Tikva, Israel

Bidding war between Teva and Endo for NuPathe

Israel’s Teva Pharmaceutical Industries Ltd offered to buy U.S. neurology drugs maker NuPathe Inc for $114 million plus milestone payments related to NuPathe’s Zecuity migraine treatment.

Big Pharma, Teva maybe ready for an acquisition

Turmoil continues at big pharma, Teva Pharmaceutical Industries, which this week tried to dispel a report of company expectations of a dramatic decline in profit for its best-selling drug, and last week was suggested to be a possible takeover target by other drugmakers.

Dealtalk: Teva’s Levin – We’re looking to expand to Brazil and China

In Dealtalk, Teva’s CEO has expressed that the big pharma company are looking to expand into Brazil and China.

Pharma partnering with Teva: Asking, thinking, discovering to become partner of choice

Teva Pharmaceuticals, a top pharma company is active engaged in pharma partnering, licensing and M&A in branded, generic and specialty pharmaceuticals

Teva Pharmaceuticals M&A activity 2005-2013

Teva has announced 13 M&A deals since 2005, with the lead deals being the acquisitions of Cephalon, Ratiopharm and Barr Pharmaceuticals

Pharmaceutical deals review for Teva: 2005-2013

Teva announced over 110 partnering / licensing, pharmaceutical deals since 2005, with 15 deals in 2012 alone

Teva: Company profile

Teva Pharmaceuticals, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

A pharma partners deal between Galena Biopharma and Teva

In a pharma partners deal, Galena Biopharma has signed an agreement with a subsidiary of Teva Pharmaceutical Industries Limited for the commercialization of NeuVax (nelipepimut-S or E75) in Israel.

A M&A run: Teva Pharma & AstraZeneca compete for Amarin

Teva Pharmaceutical Industries , the world’s largest generics drugmaker, is a leading candidate in the m&a race,  to buy Irish bio pharmaceutical company Amarin , Israel’s Calcalist financial daily reported on Thursday


Sorry, your search returned no results.


Teva bids to acquire Mylan as Perrigo rejects approach

Teva Pharmaceutical announced a proposal to acquire all of the outstanding shares of Mylan in a transaction valued at $40 billion

Teva acquires Auspex for $3.2 billion

Teva and Auspex Pharmaceuticals have entered into a definitive merger agreement

Teva enters into pharma licensing deal with Eagle Pharmaceuticals for cancer drug

Teva Pharmaceutical Industries has entered into a $120 million pharma licensing agreement that will allow it to distribute and promote a competitor to its own cancer drug, Eagle Pharmaceuticals EP-3102.

Teva bags Labrys for $825 million

Teva Pharmaceutical Industries announced that Teva has entered into a definitive m&a agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities.

Teva forms a pharma alliance with Volunteers in Medicine

Teva Pharmaceuticals USA and Volunteers in Medicine announced their 2014 pharma alliance to make healthcare services more readily available to the uninsured.

Pharma licensing deal between MDxHealth and Teva

MDxHealth has signed an exclusive pharma licensing agreement with Teva Pharmaceuticals for commercialization of ConfirmMDx for Prostate Cancer and PredictMDx for Glioblastoma tests in Israel.

Latest M&A news: Teva to acquire Nupathe

Latest M&A news is that Nupathe rejects the acquisiton offer by  Endo Health soultion and has agreed to be acquired by Teva Pharmaceuticals for $144 million in cash.

Teva and Takeda enter into a pharma licensing deal in Japan

Teva entered pharma licensing with Takeda  to commercialize Teva’s innovative glatiramer acetate formulation for the treatment of multiple sclerosis, in Japan.

Big Pharma, Teva pays $565 million in taxes

Teva, a big pharma in Israel, pays the Israel government $565 million taxes due to trapped profits. 

Cancer Research Technology pharma deals Teva Pharmaceuticals for cancer drugs

Cancer Research Technology and Teva Pharmaceutical have entered pharma deals and signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response processes in cancer cells.